Clik here to view.
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of...
BEIJING InnoCare Pharma (HKEX: 09969) announced today that the first patient was dosed in the phase II registrational trial (Registry number: CTR20221519) of tafasitamab in combination with...
View ArticleClik here to view.
Exscientia将参加于9月份召开的投资者会议
英格兰牛津 (美国商业资讯)–Exscientia (Nasdaq: EXAI)今天宣布，公司管理层将于9月份出席以下投资者会议： 摩根士丹利全球医疗年会： 日期：2022年9月14日（周三） 时间：英国夏令时间下午3:35/美国东部时间上午10:35 地点：纽约州纽约市 参会人员：首席财务官兼首席战略官Ben Taylor和首席运营官Dave Hallett 美银证券全球医疗会议：...
View ArticleClik here to view.
エクセンシアが9月に開催される投資家会議に参加
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq：EXAI）は本日、当社経営陣が9月に開催される下記の投資家会議に参加すると発表しました： モルガン・スタンレー年次グローバル・ヘルスケア会議： 開催日：2022年9月14日（水） 時刻：英国時間午後3時35分、米国東部時間午前10時35分 場所：ニューヨーク州ニューヨーク 参加者：Ben...
View ArticleClik here to view.
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
DS-7300 Continues to Show Promising Durable Response in Patients with Several...
TOKYO, BASKING RIDGE, N.J. & NASHVILLE, Tenn. Daiichi Sankyo (TSE: 4568) and Sarah Cannon Research Institute (SCRI) announced that extended follow-up data from a phase 1/2 trial of DS-7300, a...
View ArticleClik here to view.
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in...
TOKYO & BASKING RIDGE, N.J. Detailed positive results from an interim analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated clinically meaningful...
View ArticleClik here to view.
Rhizen Pharmaceuticals...
スイス・バーゼル （ビジネスワイヤ） — スイスに拠点を置く非公開の臨床段階バイオ製薬企業であるRhizen Pharmaceuticals AG（Rhizen）は本日、2022年9月9～13日にパリで開催予定のESMO 2022において、局所進行性／転移性乳がんを対象に進行中のテナリシブの第2相試験のデータおよび完了したRP12146の用量漸増相試験のデータを報告すると発表しました。...
View ArticleClik here to view.
AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug...
NEW YORK & SEOUL, South Korea AnHeart Therapeutics and NewG Lab Therapeutics, a subsidiary of NewG Lab Pharma, announced that the Ministry of Food and Drug Safety (MFDS), Republic of Korea has...
View ArticleClik here to view.
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating...
BOTHELL, Wash. & TOKYO & RAHWAY, N.J. Seagen Inc. (Nasdaq:SGEN), Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Merck (NYSE: MRK), known as MSD...
View ArticleClik here to view.
CANbridge Pharmaceuticals to Participate in Two Investor Conferences in...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals, Inc. (HKEX:1228) , a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
PDC*line Pharma Presents First Clinical Results From Phase I/II trial With...
LIÈGE, Belgium & GRENOBLE, France PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the first...
View ArticleClik here to view.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China
BEIJING InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration)...
View ArticleClik here to view.
Rhizen Pharmaceuticals AG宣布即将在ESMO...
瑞士巴塞尔 (美国商业资讯)–总部位于瑞士的私营临床阶段生物制药公司Rhizen Pharmaceuticals AG (Rhizen)今天宣布，于2022年9月9日至13日在巴黎举行的2022年欧洲肿瘤内科学会年会(ESMO 2022)上展示正在进行的Tenalisib治疗局部晚期或转移性乳腺癌的II期试验数据，以及RP12146的剂量递增阶段的结论数据。...
View ArticleClik here to view.
METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi
CAMBRIDGE, Mass. METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a license agreement with Voronoi,...
View ArticleClik here to view.
Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7...
SEONGNAM-SI, South Korea Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the company has entered into a clinical collaboration agreement with...
View ArticleClik here to view.
百奥赛图与泛恩生物达成基于类TCR抗体的细胞治疗药物开发合作
北京，广州 百奥赛图（北京）医药科技股份有限公司（简称“百奥赛图”，股票代码：02315.HK）宣布与广州泛恩生物科技有限公司（简称“泛恩生物”）达成合作协议，百奥赛图将利用其自主开发的类TCR抗体技术平台筛选针对特定靶点的全人抗体序列，结合泛恩生物特有的细胞治疗技术平台，共同开发针对胞内肿瘤相关抗原的创新性细胞治疗药物。...
View ArticleClik here to view.
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic...
BEIJING & GUANGZHOU, China Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD....
View ArticleClik here to view.
The Dragonfly Foundation Receives SBB Research Group Foundation Grant
CHICAGO The Chicago Chapter of the Dragonfly Foundation received a $5,000 grant from the SBB Research Group Foundation, which awards monthly grants to support impactful organizations during the...
View ArticleClik here to view.
知临集团提供 RPIDD 传染病液体活检分子诊断临床验证的最新資訊
纽约、伦敦和巴黎 (美国商业资讯)–知临集团（纳斯达克股票代码：APM，巴黎泛欧交易所股票代码：APM）是一家临床阶段的生物制药公司，致力于解决肿瘤学、自身免疫性疾病和传染病方面未满足的医疗需求。知临集团很高兴地宣布更多地在 Illumina iSeq 100 和 MiniSeq 测序平台1下使用RPIDD 技术分析、以及回顾性和前瞻性临床验证患者样本的最新資訊。 迄今为止，RPIDD...
View ArticleClik here to view.
Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles...
BRISTOL, N.J. & SEOUL Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it...
View Article